Company details multi-year Joint Preservation strategy for accelerated revenue growth and profitability Updates 2021 directional outlook and 2024 multi-year targets BEDFORD, Mass. , June 03, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in
BEDFORD, Mass. , May 13, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to host its 2021 Virtual Investor Day on Thursday, June 3, 2021 beginning at 9:00am EDT .
Revenue lower by 3% versus pre-COVID in prior year Joint Preservation revenue up 55% as transformative mix shift continues Company on track to achieve stated revenue growth in 2021 BEDFORD, Mass. , May 06, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc.
BEDFORD, Mass. , May 04, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard , President and Chief Executive Officer and Michael Levitz , Executive Vice President, Chief
BEDFORD, Mass. , April 15, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its first quarter 2021 financial results after the close of the market on Thursday, May
BEDFORD, Mass. , April 05, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard , President and Chief Executive Officer and Michael Levitz , Executive Vice President, Chief
BEDFORD, Mass. , March 11, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard , President and Chief Executive Officer and Michael Levitz , Executive Vice President, Chief
Completed Transformative Year with Q4 2020 Revenue Up 10% Year-Over-Year, Full Year 2020 Revenue up 14% Well Positioned for Growth in 2021 BEDFORD, Mass. , March 04, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company that creates and delivers
BEDFORD, Mass. , Feb. 09, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, today announced that the Company plans to issue its fourth quarter and year-end
Revenue Increased 7% Year-over-Year to $ 31.7 Million Repaid $25 M illion of Outstanding Credit Facility Continued Expansion of Joint Preservation Product Portfolio BEDFORD, Mass. , Nov. 04, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company
